G Protein News and Research

RSS

H1N1 vaccine: Discussions and debates

You can't avoid H1N1 media coverage. It's front-page news on the web, the presses, the airways. Vaccine details, or lack of, are spurring discussion and debate. And a lot of people are in a quandary about whether or not to have the H1N1 shot based on their personal views and the information disseminated for public knowledge.

4 Nov 2009

The Children’s Hospital leads the charge against childhood obesity

The Children’s Hospital is leading the charge against childhood obesity, a problem that is impacting more and more families across the country. Experts from The Children’s Hospital offer a pediatric perspective on proactive steps parents can take to ensure their children maintain nutritious diets and healthy, active lifestyles.

4 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Scientists discover two genes that can lead to aggressive leukaemia

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

3 Nov 2009

NIH awards Trevena $7.65M Grand Opportunity grant

Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena’s work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.

3 Nov 2009

Two cancer-causing genes together can lead to aggressive leukaemia

3 Nov 2009

A new blood test for breast cancer

A healthy 44-year-old woman will celebrate many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new blood test for breast cancer

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Pateamine A found to inhibit yet another anti-cancer mechanism

Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.

3 Nov 2009

Cambridge Research & Instrumentation launches inForm image analysis software

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the launch of inForm™, advanced image analysis software based on the company’s proprietary Machine Learning System (MLS). inForm solves biologists’ and cancer researchers’ challenging image analysis problems by combining fast and easy-to-use automated image processing with advanced learning features that enable the user to train the software to process images automatically.

3 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

ISB and Complete Genomics embark on the largest complete human genome disease association study

The Institute for Systems Biology (ISB) and Complete Genomics Inc. announced today that they are embarking on a large-scale human genome sequencing study of Huntington’s disease (HD). ISB has engaged Complete Genomics to sequence 100 genomes, the majority of which will be used to investigate this disease, with samples from affected individuals, family members, and matched controls to study modifiers of disease presentation and progression.

2 Nov 2009

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA).

2 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Nuevolution receives milestone payment from Merck

Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

G Protein News and Research

H1N1 vaccine: Discussions and debates

The Children’s Hospital leads the charge against childhood obesity

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Scientists discover two genes that can lead to aggressive leukaemia

NIH awards Trevena $7.65M Grand Opportunity grant

Two cancer-causing genes together can lead to aggressive leukaemia

A new blood test for breast cancer

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

Phase 1 study of STX107 for Fragile X syndrome begins

Pateamine A found to inhibit yet another anti-cancer mechanism

Cambridge Research & Instrumentation launches inForm image analysis software

NIH awards $2 million grant for sickle cell disease research

ISB and Complete Genomics embark on the largest complete human genome disease association study

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Nuevolution receives milestone payment from Merck

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Combination of inhibitor and antioxidants may help prevent diabetes complications

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News